Mycronic ABOMXSTO: MYCR

MYCR: Q2 delivered robust sales and EBIT growth, offset by lower order intake and active M&A

· Issued by Mycronic AB

Q2 saw 35% sales growth and a 27% EBIT margin, with strong performance in Pattern Generators and High Volume, but order intake declined due to no new system orders. Three acquisitions and a share split were completed, and full-year sales guidance was reaffirmed at SEK 7.5 billion.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Mycronic AB on 6ix

In the deck

Story so far

Earlier from Mycronic

Later from Mycronic

All Mycronic news releases